Prior immunosuppressant use ups Tysabri PML risk

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1350, 2011-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PML risk testing: should Tysabri manufacturers have faith in JC?

Reactions Weekly, Vol. 1, Iss. 1319, 2010-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Third report of Tysabri-linked PML in commercial setting

Reactions Weekly, Vol. 1, Iss. 1227, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Third report of Tysabri-linked PML in commercial setting

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

EMEA's CHMP has recommended updating the product information for natalizumab [Tysabri] to further increase the awareness about risk of progressive multifocal leukoencephalopathy (PML)

Reactions Weekly, Vol. 1, Iss. 1222, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

No new confirmed cases of progressive multifocal leukoencephalopathy (PML) associated with Tysabri [natalizumab]

Reactions Weekly, Vol. 1, Iss. 1075, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite